Carigent Therapeutics

Carigent Therapeutics is a biotechnology company that was established to develop site-specific drug delivery systems using a proprietary bioadhesive nanoparticle (BNP) platform. Spun out of Yale University, the company's technology was designed to enhance the therapeutic index of drugs by increasing their local concentration and residence time at the target site while minimizing systemic exposure. Carigent's primary focus was on oncology, particularly glioblastoma multiforme and other solid tumors, where its platform could deliver various payloads including small molecules and nucleic acids. The company's approach aimed to overcome significant barriers in drug delivery, such as the blood-brain barrier and rapid clearance from the target tissue. By utilizing biodegradable polymers like PLGA, Carigent developed treatments that provided sustained release of encapsulated payloads, such as camptothecin. The company's technology represents a significant advancement in localized therapy for difficult-to-treat cancers.